John J. Tentler

Publications

• Antitumor Activity of the Aurora a Selective Kinase Inhibitor, Alisertib, Against Preclinical Models of Colorectal Cancer
  Oncotarget. Jul, 2016  |   Pubmed ID: 27385211
• An Integrated Bioinformatics Analysis to Dissect Kinase Dependency in Triple Negative Breast Cancer
  BMC Genomics. 2015  |   Pubmed ID: 26681397
• Antitumor Activity of a Potent MEK Inhibitor, TAK-733, Against Colorectal Cancer Cell Lines and Patient Derived Xenografts
  Oncotarget. Oct, 2015  |   Pubmed ID: 26439693
• Combined Inhibition of MEK and Aurora A Kinase in KRAS/PIK3CA Double-mutant Colorectal Cancer Models
  Frontiers in Pharmacology. 2015  |   Pubmed ID: 26136684
• P53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer
  Molecular Cancer Therapeutics. May, 2015  |   Pubmed ID: 25758253
• Antitumor Activity of the MEK Inhibitor TAK-733 Against Melanoma Cell Lines and Patient-derived Tumor Explants
  Molecular Cancer Therapeutics. Feb, 2015  |   Pubmed ID: 25376610
• Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer
  PloS One. 2014  |   Pubmed ID: 25401499
• Triple-negative Breast Cancer: Bridging the Gap from Cancer Genomics to Predictive Biomarkers
  Therapeutic Advances in Medical Oncology. May, 2014  |   Pubmed ID: 24790649
• Overcoming IGF1R/IR Resistance Through Inhibition of MEK Signaling in Colorectal Cancer Models
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Nov, 2013  |   Pubmed ID: 24045180
• Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Aug, 2013  |   Pubmed ID: 23757356
• MERTK Receptor Tyrosine Kinase is a Therapeutic Target in Melanoma
  The Journal of Clinical Investigation. May, 2013  |   Pubmed ID: 23585477
• Association of the Epithelial-to-mesenchymal Transition Phenotype with Responsiveness to the P21-activated Kinase Inhibitor, PF-3758309, in Colon Cancer Models
  Frontiers in Pharmacology. 2013  |   Pubmed ID: 23543898
• Role of Ubiquitin Ligases and the Proteasome in Oncogenesis: Novel Targets for Anticancer Therapies
  Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Mar, 2013  |   Pubmed ID: 23358974
• CtBP1 is Expressed in Melanoma and Represses the Transcription of P16INK4a and Brca1
  The Journal of Investigative Dermatology. May, 2013  |   Pubmed ID: 23303449
• Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jan, 2013  |   Pubmed ID: 23136197
• ATM and MET Kinases Are Synthetic Lethal with Nongenotoxic Activation of P53
  Nature Chemical Biology. Jul, 2012  |   Pubmed ID: 22660439
• Patient-derived Tumour Xenografts As Models for Oncology Drug Development
  Nature Reviews. Clinical Oncology. Jun, 2012  |   Pubmed ID: 22508028
• Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-mutant Colorectal Cancer Models
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Feb, 2012  |   Pubmed ID: 22173548
• Mapping of ESE-1 Subdomains Required to Initiate Mammary Epithelial Cell Transformation Via a Cytoplasmic Mechanism
  Molecular Cancer. 2011  |   Pubmed ID: 21871131
• The Insulin-like Growth Factor I Receptor/insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Nov, 2010  |   Pubmed ID: 20943761
• Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras-mutated Colorectal Cancer
  Molecular Cancer Therapeutics. Dec, 2010  |   Pubmed ID: 20923857
• Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jun, 2010  |   Pubmed ID: 20530704
• Assessment of the in Vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, Against Primary and Cell Line-derived Human Colorectal Cancer Xenograft Models
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jun, 2010  |   Pubmed ID: 20406842
• Targeting Vascular Endothelial Growth Factor Receptor-1 and -3 with Cediranib (AZD2171): Effects on Migration and Invasion of Gastrointestinal Cancer Cell Lines
  Molecular Cancer Therapeutics. Sep, 2009  |   Pubmed ID: 19755510
• Vorinostat and Bortezomib Exert Synergistic Antiproliferative and Proapoptotic Effects in Colon Cancer Cell Models
  Molecular Cancer Therapeutics. Feb, 2009  |   Pubmed ID: 19174560
• Structural and Functional Analysis of the Differential Effects of C-Jun and V-Jun on Prolactin Gene Expression
  Molecular Endocrinology (Baltimore, Md.). Oct, 2004  |   Pubmed ID: 15231872
• ESX Induces Transformation and Functional Epithelial to Mesenchymal Transition in MCF-12A Mammary Epithelial Cells
  Oncogene. Mar, 2004  |   Pubmed ID: 14767472
• The Epithelial-specific ETS Transcription Factor ESX/ESE-1/Elf-3 Modulates Breast Cancer-associated Gene Expression
  DNA and Cell Biology. Feb, 2003  |   Pubmed ID: 12713734
• Selective Repression of Rat Prolactin Gene by Stable Expression of Dominant-negative Ets in GH4 Pituitary Cells
  Endocrine. Feb-Mar, 2003  |   Pubmed ID: 12668863